India Dedicates First Indigenous H5N1 Bird Flu Vaccine in Bhopal

Union Minister for Agriculture and Farmers' Welfare and Rural Development Shivraj Singh Chouhan dedicated India's first indigenous chicken vaccine against Avian Influenza (H5N1) to the nation in Bhopal on November 20, 2026. Developed by the ICAR-National Institute of High Security Animal Diseases (NIHSAD) in Bhopal, the vaccine is priced at Rs 1 to Rs 2 per dose and was described in a Press Information Bureau (PIB) release as the world's first vaccine against this particular variant of bird flu.
Rs 300-Crore Lab and Bhopal Launch
At the ceremony, Chouhan unveiled plans for a Rs 300-crore high-tech animal disease research laboratory in Bhopal, according to a PIB release. While an initial plan suggested launching the vaccine in Delhi, Chouhan opted for Bhopal so the recognition would happen alongside the researchers who created it and the local community.
Economic Burden and Outbreak History
Describing livestock as "moving ATMs" that provide monthly rural income, Chouhan noted that animal husbandry generates 14 per cent of India's GDP alongside 1 per cent from poultry. He cited annual livestock disease losses totalling approximately Rs 56,000 crore, comprising Rs 22,000 crore from Foot and Mouth Disease, Rs 20,000 crore from Lumpy Skin Disease, Rs 9,212 crore from Brucellosis, and Rs 4,683 crore from Peste des Petits Ruminants in sheep and goats. Recalling India's bird flu history, the Minister said the first outbreak in Navapur, Maharashtra in 2006 killed 10 lakh chickens and forced the culling of lakhs more, followed by around 9 lakh chicken deaths in 2021 and another 2 lakh deaths in 2026 across more than 500 outbreaks since 2006. Because the disease also carries a risk of transmission to mammals and humans, Chouhan said the Rs 1 to Rs 2 dose price is meant to keep preventive vaccination affordable for small poultry farmers.
National Vaccination Drive and Political Remarks
Reviewing broader animal health programmes, Chouhan noted that 147 crore 16 lakh free vaccine doses have been administered against Foot and Mouth Disease under the National Animal Disease Control Program launched by Prime Minister Narendra Modi from Mathura. He added that Brucellosis has been brought under control and recalled that after Lumpy Skin Disease infected 32 lakh 80 thousand animals and killed 1 lakh 86 thousand in 2022, scientists at Hisar and Izatnagar developed the Lumpi-ProVacInd vaccine. Earlier domestic vaccines developed at NIHSAD Bhopal include shots targeting African Swine Fever, Classical Swine Fever, Brucella abortus S-19 Delta, and Gumboro disease.
Chouhan also used the platform to criticise opposition leaders who question India's constitutional institutions, armed forces, and scientists while speaking abroad, recalling that Indian scientists earlier developed two indigenous COVID-19 vaccines in nine months. Madhya Pradesh Minister Vishwas Sarang, Bhopal MP Alok Sharma, Khategaon MLA Ashish Sharma, Bhopal Mayor Malti Rai, ICAR Director General Dr. M. L. Jat, and NIHSAD Director Dr. Aniket Sanyal attended the Bhopal ceremony.
Background
Farmers must continue complying with official reporting, sampling, movement-control, and outbreak-response directions until authorities formally communicate a policy change, and should not buy or administer advertised products before an approved label and official veterinary guidance are available, according to Pashudhan Praharee.
NIHSAD reported that experimental trials in specific pathogen-free layer and grower chickens met sterility, safety, and efficacy standards, protected chickens for up to six months, and prevented transmission to birds kept in contact with vaccinated chickens, according to The Times of India.
Veterinary authorities state that the November 2026 unveiling is a scientific achievement rather than regulatory authorization for field vaccination, and commercial and emergency H5N1 vaccination remains strictly prohibited in India, according to PoultryMed.
DAHD's structured HPAI vaccine pathway requires CDSCO approval for importing vaccine strains, bridging studies using Indian field strains, evaluation under HSADL Bhopal guidance, pre-commercialization regulatory review, and mandatory post-deployment surveillance, according to Benison Media.
In December 2022, Hester Biosciences acquired technology from ICAR-NIHSAD for an inactivated low pathogenic avian influenza (H9N2) chicken vaccine and later received a manufacturing licence, according to Business Upturn.
Sources & Citations
- PibPrimary / official
- News On AIRPrimary / official
- PoultryMed
- TOI
- Pashudhan Praharee
- Business Upturn
- Press Information BureauPrimary / official
- Website-files
- Deccan Chronicle
- Asian Agribiz
- Benison Media
- TOI
